A study shows that Romanian patients wait, on average, 460 days for access to innovative medicines, seriously affecting critical areas such as oncology.
Andreea Lificiu
Health
https://www.pexels.com/
Always see our news on Google
An analysis carried out by Novartis Romania highlights the long delays in Romanian patients' access to innovative medicines, with an average of 460 days from the approval of compensation by the ANMDM. Oncology is the most affected, with 40% of the indications analyzed. Although the assessment process has improved, the compensation steps remain lengthy. The study emphasizes the need for reforms in the reimbursement system to ensure rapid and equitable access to treatment.
Sources
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate/ Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Latest News
16:31
Nicușor Dan challenged at the Constitutional Court the AUR amendment to the ANI Law, which requires the partners of dignitaries to submit asset and interest declarations.
16:21
CNAIR will inaugurate a new section of the A3 Transylvania Highway tomorrow.
16:10
Italy officially recognizes the Romanian Orthodox Episcopate
16:09
Bulgaria demands explanations from Ukraine after a drone entered its airspace
16:09
Germany has implemented a reform of social benefits that clarifies the rules for beneficiaries who do not attend mandatory appointments.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
